Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience Inc. (TSE:MSCL)
:MSCL
MSCL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.45 - C$1.32
Previous CloseN/A
Volume29.01K
Average Volume (3M)98.24K
Market Cap
C$102.26M
Enterprise ValueC$68.40M
Total Cash (Recent Filing)C$41.19M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Sep 01, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding176,305,360
10 Day Avg. Volume72,915
30 Day Avg. Volume98,237
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.25Price Target Upside116.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has made significant progress, well positioning itself for the next value inflection point.
Drug SafetyPhase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.
Bears Say
Financial PerformanceThe company reported no revenue, in line with the consensus estimate, and a net loss.
Satellos Bioscience News
MSCL FAQ
What was Satellos Bioscience Inc.’s price range in the past 12 months?
Satellos Bioscience Inc. lowest stock price was C$0.45 and its highest was C$1.32 in the past 12 months.
What is Satellos Bioscience Inc.’s market cap?
Satellos Bioscience Inc.’s market cap is C$102.26M.
When is Satellos Bioscience Inc.’s upcoming earnings report date?
Satellos Bioscience Inc.’s upcoming earnings report date is Sep 01, 2025 which is in 25 days.
How were Satellos Bioscience Inc.’s earnings last quarter?
Currently, no data Available
Is Satellos Bioscience Inc. overvalued?
According to Wall Street analysts Satellos Bioscience Inc.’s price is currently Undervalued.
Does Satellos Bioscience Inc. pay dividends?
Satellos Bioscience Inc. does not currently pay dividends.
What is Satellos Bioscience Inc.’s EPS estimate?
Satellos Bioscience Inc.’s EPS estimate is -0.03.
How many shares outstanding does Satellos Bioscience Inc. have?
Satellos Bioscience Inc. has 176,305,360 shares outstanding.
What happened to Satellos Bioscience Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Satellos Bioscience Inc.?
Currently, no hedge funds are holding shares in TSE:MSCL
Satellos Bioscience Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$1.25 (116.12% Upside)
C$1.25 (116.12% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.96%
12-Months-Change
Fundamentals
Return on Equity
-64.18%
Trailing 12-Months
Asset Growth
56.95%
Trailing 12-Months
Company Description
Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience (MSCL) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
MSCL Stock 12 Month Forecast
Average Price Target
C$1.25
▲(116.12% Upside)
Technical Analysis
Oncolytics Biotech
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Sernova
―
Gemina Laboratories Ltd.
―
Ownership Overview
22.30% Insiders
0.66%
Mutual Funds
― Other Institutional Investors
77.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---